[Radioimmunotherapy for treatment of acute myeloid leukaemia and myelodysplastic syndrome: conceptual chances].
The prognosis of patients with acute myeloid leukaemia (AML) has improved considerably by introduction of aggressive consolidation chemotherapy and haematopoietic stem cell transplantation (SCT). Nevertheless, only 20-30% of patients with AML achieve long-term disease-free survival after SCT. The most common cause of treatment failure is relapse. Additionally, mortality rates are significantly increased by therapy-related causes such as toxicity of chemotherapy and complications of SCT. Including radioimmunotherapies in the treatment of AML and myelodyplastic syndrome (MDS) allows for the achievement of a pronounced antileukaemic effect for the reduction of relapse rates on the one hand. On the other hand, no increase of acute toxicity and later complications should be induced. These effects are important for the primary reduction of tumour cells as well as for the myeloablative conditioning before SCT. This paper provides a systematic and critical review of the currently used radionuclides and immunoconjugates for the treatment of AML and MDS and summarizes the literature on primary tumour cell reductive radioimmunotherapies on the one hand and conditioning radioimmunotherapies before SCT on the other hand.
Buchmann
I
I
Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Mainz, Langenbeckstr. 1, 55101 Mainz. buchmann@nuklear.klinik.uni-mainz.de
Meyer
R G
RG
Herr
W
W
Helisch
A
A
Bartenstein
P
P
D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000532:radiotherapy*; D009190:Myelodysplastic Syndromes / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D012008:Recurrence; D015203:Reproducibility of Results